Joshua Crawley
Biography
Overview
Joshua Crawley is an associate in our global M&A and Corporate practice based in London. He is a member of our EMEA Private Equity team.
Joshua focuses on private equity acquisitions and equity investments. He also advises on a broad range of corporate transactions (including domestic, cross-border and global mergers and acquisitions) and management teams in relation to the equity incentive arrangements.
upon Tyne
Experience
Representation of Triton:
- on its £1.3 billion recommended takeover offer for Clinigen Group plc, through funds managed by leading private equity firm Triton.
- on the acquisition of O'Connor Trading Holdings Limited, the holding company of a leading UK multi-utility services specialist business operating within regulated infrastructure, from its founders Tim and Tom O'Connor.
Representation of CVC Growth on its acquisition of Brightstarr Group (Unily), a market leading Ex SaaS platform enhancing employee engagement for global enterprises with subsidiaries in the US and Australia.
Representation of Morgan Stanley Infrastructure Partners, global leader in private infrastructure equity investing, on its sale of its 50% interest in in Höegh Evi, a global provider of liquified natural gas and floating energy infrastructure, to Igneo Infrastructure Partners.
Representation of Oaktree Capital Management and Cornerstone Investment Management on their sale of Avenga, a software engineering and consulting services provider, to KKCG, a Czech private investment group.
Representation of Oaktree Capital Management (UK) LLP in its acquisition of the OEG Group (one of the leading offshore cargo carrying equipment suppliers in the world) via the Oaktree Power Opportunities Fund.
Representation of Clinigen Limited, a global pharmaceutical and services company that provides access to clinical trials, medicines, unlicensed and commercial supplies, on its sale of Proleukin® to Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ('Iovance'), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumour infiltrating lymphocyte (TIL) and peripheral-blood lymphocyte (PBL)).
